- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07931352
Evaluation of the Effects of Anti-TNF Therapy on the Retina in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
EVALUATION OF THE EFFECTS OF ANTI-TNF THERAPY ON THE RETINA IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
This prospective observational cohort study evaluates whether anti-tumor necrosis factor (anti-TNF) therapy changes the retinal and choroidal microvasculature and retinal structure in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Patients for whom the rheumatology clinic decided to start anti-TNF therapy as part of routine care are compared with patients who continue treatment without anti-TNF agents. All participants undergo a complete eye examination, optical coherence tomography (OCT) and OCT angiography (OCTA) before treatment and at month 6. The main question is whether retinal vessel density changes differently over time between the two groups.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Background: Chronic systemic inflammation in RA and AS has been associated with endothelial dysfunction and microvascular changes. TNF-alpha is a key mediator of this inflammation, and anti-TNF agents are widely used in both diseases. Prospective data on retinal and choroidal microvasculature with measurements taken before the start of anti-TNF therapy are limited.
Design and participants: Patients with RA or AS followed at the Rheumatology Clinic of Ankara Bilkent City Hospital were referred to the Ophthalmology Clinic between October and December 2025. Treatment decisions were made by the treating rheumatologists, independently of the study. The anti-TNF group consists of anti-TNF-naive patients for whom anti-TNF therapy was planned; their baseline examination was performed before the first dose. The control group consists of patients who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up.
Assessments: At baseline and month 6, all participants undergo best-corrected visual acuity (logMAR), Goldmann applanation tonometry, slit-lamp biomicroscopy and dilated fundus examination with a +90 D lens. OCT (Heidelberg Spectralis) is used to measure central and sectoral macular thickness, peripapillary retinal nerve fiber layer (RNFL) thickness (global and six sectors) and ganglion cell layer (GCL) thickness. OCTA (RTVue XR Avanti with AngioVue, Optovue) is performed with fovea-centred 6x6 mm scans. Superficial (SCP) and deep capillary plexus (DCP) vessel density are recorded for the whole image, superior and inferior hemifields, and foveal, parafoveal and perifoveal regions with four sectors. Foveal avascular zone (FAZ) area, FAZ perimeter, acircularity index, foveal vessel density and choriocapillaris flow area are also recorded. 3D projection artifact removal is applied. Scans with a quality (Q) score below 6, significant motion or projection artifacts, or segmentation errors are excluded. All examinations are performed by the same, unmasked examiner. ESR and CRP values closest to each visit are obtained from hospital records.
Statistical analysis: Eye-level data are analysed with linear mixed models adjusted for age and sex. The treatment effect is assessed by the group-by-time interaction. The study is reported according to the STROBE guideline.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
Ankara, Turecko (Türkiye)
- Ankara Bilkent City Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adult patients with rheumatoid arthritis or ankylosing spondylitis followed at the Rheumatology Clinic of Ankara Bilkent City Hospital and referred to the Ophthalmology Clinic between October and December 2025.
Popis
Inclusion Criteria:
- Age 18 to 75 years
- Diagnosis of rheumatoid arthritis or ankylosing spondylitis
- Receiving treatment for RA or AS (conventional therapy, planned initiation of anti-TNF therapy, or continued conventional non-biologic therapy)
- Willingness to participate and written informed consent
Exclusion Criteria:
-
• History of retinal disease (e.g., diabetic retinopathy, age-related macular degeneration, retinal vein occlusion)
- Ocular disease that may affect OCT measurements or visual field, such as glaucoma, optic neuropathy or dense cataract
- Uveitis, diabetes mellitus or systemic hypertension
- Previous ocular surgery or laser treatment, or high refractive error
- Pregnancy or breastfeeding
- Treatment with non-TNF biologic agents (e.g., abatacept, rituximab)
- OCTA scan quality (Q) score below 6
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
|---|---|
|
Anti-TNF group
Anti-TNF-naive patients with RA or AS for whom the treating rheumatologist planned to start anti-TNF therapy as part of routine care. The baseline examination was performed before the first dose. |
adalimumab, etanercept, golimumab
Ostatní jména:
|
|
Control group
Patients with RA or AS who were not receiving anti-TNF therapy at baseline and did not start it during the 6-month follow-up. They continued conventional (non-biologic) treatment. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in superficial capillary plexus whole-image vessel density
Časové okno: Baseline and month 6
|
SCP vessel density (%) in fovea-centred 6x6 mm OCTA scans (AngioVue, Optovue). Change from baseline to month 6 is compared between groups (group-by-time interaction). |
Baseline and month 6
|
|
Change in deep capillary plexus whole-image vessel density
Časové okno: Baseline and month 6
|
DCP vessel density (%) in fovea-centred 6x6 mm OCTA scans. Change from baseline to month 6 is compared between groups. |
Baseline and month 6
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Erythrocyte sedimentation (mm/h) rate
Časové okno: Baseline and month 6
|
Change in systemic inflammatory marker obtained from hospital records. |
Baseline and month 6
|
|
C-reactive protein (mg/L) value
Časové okno: Baseline and month 6
|
Change in systemic inflammatory marker obtained from hospital records. |
Baseline and month 6
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Yasin Toklu, Professor Doctor, Ankara City Hospital Bilkent
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Axiální spondylartritida
- Nemoci kostí
- Nemoci pohybového aparátu
- Artritida
- Onemocnění kloubů
- Revmatická onemocnění
- Nemoci pojivové tkáně
- Autoimunitní onemocnění
- Onemocnění imunitního systému
- Nemoci páteře
- Spondylartropatie
- Ankylóza
- Spondylartritida
- Spondylitida
- Onemocnění kůže a pojivové tkáně
- Spondylitida, ankylozující
- Artritida, revmatoidní
Další identifikační čísla studie
- TABED 1-25-1729
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data will not be shared publicly. Aggregate results will be reported in scientific publications.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .